PTN PALATIN TECHNOLOGIES INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 911216 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-276.9%
TTM EPS YoY-4.0%
Revenue 3-yr CAGR-61.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,354.1%
Net margin-5,261.5%
FCF margin—
EBITDA margin-5,335.2%
Returns
ROE-1,495.4%
ROA-271.7%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets57.1%
Debt / equity0.00x
Current ratio1.67x
Interest coverage-2,873.67x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-36.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $361,802 | -$4.05M | $3.92M | $116,036 | $8.83M | $0 | $0 | — |
| R&D expense | $3.38M | $2.01M | $3.52M | $4.32M | $2.53M | $1.97M | $3.76M | $3.43M |
| SG&A expense | $2.08M | $2.71M | $1.98M | $3.12M | $1.66M | $2.63M | $1.47M | $1.68M |
| Operating income | -$5.10M | -$4.42M | -$1.58M | -$7.33M | $4.66M | -$2.27M | -$4.81M | -$2.61M |
| Interest expense | $1,690 | $2,958 | $1,268 | $498 | $2,002 | $3,487 | $1,795 | $3,803 |
| Net income | -$5.06M | -$4.36M | -$1.43M | -$7.26M | $4.68M | -$2.23M | -$4.81M | -$2.44M |
| EBITDA | -$5.09M | -$4.40M | -$1.56M | -$7.31M | $4.68M | -$2.22M | -$4.76M | -$2.54M |
| EPS (basic) | -1.29 | — | -0.37 | -2.86 | 4.81 | — | -9.13 | -5.92 |
| EPS (diluted) | -1.29 | — | -0.37 | -2.86 | 4.26 | — | -9.13 | -5.92 |
| Weighted avg. shares (diluted) | 3.92M | — | 3.91M | 2.54M | 1.10M | — | 526,891 | 412,697 |
| Balance sheet | ||||||||
| Cash & equivalents | $3.74M | $7.49M | $10.16M | $14.48M | $8.24M | $9.53M | $2.52M | $3.42M |
| Receivables | $361,802 | $300,770 | — | $1.64M | $6.89M | $0 | — | — |
| Current assets | $4.44M | $8.16M | $12.79M | $17.47M | $8.37M | $2.92M | $3.23M | $3.67M |
| PP&E, net | $101,112 | $118,064 | $135,016 | $113,485 | $115,057 | $129,444 | $182,437 | $235,741 |
| Total assets | $4.72M | $8.52M | $13.23M | $17.93M | $8.61M | $3.27M | $3.73M | $4.31M |
| Current liabilities | $2.66M | $1.77M | $2.54M | $6.33M | $8.22M | $8.01M | $10.05M | $9.56M |
| Total liabilities | $2.69M | $1.84M | $2.63M | $6.46M | $8.22M | $8.04M | $10.12M | $10.69M |
| Shareholders' equity | $2.03M | $6.69M | $10.59M | $11.47M | $396,399 | -$4.78M | -$6.39M | -$6.38M |
| Shares outstanding | 1.78M | 1.78M | 1.78M | 1.76M | 973,291 | 929,597 | 28.56M | 23.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.74M | -$2.69M | -$4.42M | -$4.81M | -$1.62M | -$4.09M | -$5.35M | -$4.85M |
| Capital expenditure | — | $0 | $38,483 | — | — | $0 | $0 | — |
| Free cash flow | — | -$2.69M | -$4.46M | — | — | -$4.09M | -$5.35M | — |
| Investing cash flow | — | $0 | -$38,483 | — | — | $630,000 | $0 | $2.50M |
| Financing cash flow | -$10,001 | $22,500 | $138,878 | $18.02M | $328,200 | $3.50M | $4.46M | $3.38M |
| Depreciation & amortization | $16,952 | $16,952 | $16,952 | $14,388 | $14,387 | $52,993 | $53,304 | $71,830 |
| Stock-based compensation | $407,126 | $430,668 | $419,968 | $310,740 | $167,711 | $336,612 | $347,691 | $348,955 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.